<span item_type="fundamental" item_id="ab940f1dd1b595cd873e9402b23d918e" counter_id="ST/US/GRCE" env="prod"></span><span item_type="announcement" item_id="582312465601597697" env="prod"></span><p>Revenue: As of FY2026 Q2, the actual value is USD 0.</p><p>EPS: As of FY2026 Q2, the actual value is USD -0.06.</p><p>EBIT: As of FY2026 Q2, the actual value is USD -2.701 M.</p><p></p><h3>Net Loss</h3><ul><li>Grace Therapeutics, Inc. reported a net loss of $0.9 million, or $0.06 per share, for the three months ended September 30, 2025, compared to a net loss of $3.4 million, or $0.30 per share, for the same period in 2024. The decrease in net loss was primarily due to a $2.4 million decrease in research and development expenses and a $1.1 million change in the fair value of derivative warrant liabilities, partially offset by a $0.9 million decrease in income tax benefit and a $0.1 million increase in general and administrative expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1444192/000114036125041807/ef20058656_ex99-1.htm"></span></li></ul><h3>Research and Development Expenses</h3><ul><li>Total research and development expenses for the three months ended September 30, 2025, were $0.6 million, compared to $3.0 million for the same period in 2024. The decrease of $2.4 million was primarily due to the completion of the GTx-104 pivotal Phase 3 STRIVE-ON safety trial.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1444192/000114036125041807/ef20058656_ex99-1.htm"></span></li></ul><h3>General and Administrative Expenses</h3><ul><li>General and administrative expenses were $2.0 million for the three months ended September 30, 2025, an increase of $0.1 million from $1.9 million for the same period in 2024. This increase was primarily due to costs associated with GTx-104 pre-commercial planning.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1444192/000114036125041807/ef20058656_ex99-1.htm"></span></li></ul><h3>Cash and Cash Equivalents</h3><ul><li>As of September 30, 2025, cash and cash equivalents were $16.9 million, a net decrease of $5.2 million from $22.1 million as of March 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1444192/000114036125041807/ef20058656_ex99-1.htm"></span></li></ul><h3>Cash Runway</h3><ul><li>The company estimates that its cash and cash equivalents were approximately $20.0 million as of October 31, 2025. The company believes that current cash and cash equivalents provide a cash runway through at least the next twelve months, potentially extending into the second quarter of 2027 if all common warrants issued in February 2025 are exercised.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1444192/000114036125041807/ef20058656_ex99-1.htm"></span><span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1444192/000114036125041807/ef20058656_ex99-2.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Grace Therapeutics, Inc. has received orphan drug status designation for GTx-104 from the FDA, which provides potential 7 years of marketing exclusivity in the US upon NDA approval. GTx-104 is positioned to solve oral challenges and potentially displace oral nimodipine as the standard of care.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1444192/000114036125041807/ef20058656_ex99-2.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Grace Therapeutics anticipates that if the NDA for GTx-104 is approved by the FDA, the strong U.S. and international patent estate will help maximize the long-term market value of GTx-104. The company looks forward to continuing engagement with the FDA during their review, targeting the PDUFA date of April 23, 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1444192/000114036125041807/ef20058656_ex99-1.htm"></span> The NDA for GTx-104 was filed in June 2025 and accepted for review on August 22, 2025, with a target PDUFA date of April 23, 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1444192/000114036125041807/ef20058656_ex99-2.htm"></span></li></ul>

Grace Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0